American Shared Hospital Services（AMS）资讯与事件AMSAmerican Shared Hospital Services

JPMorgan Downgrades ams OSRAM to Underweight, Price Target Cut to CHF 5.35

JPMorgan analyst Craig McDowell downgraded ams OSRAM to Underweight from Neutral with a price target of CHF 5.35, down from CHF 8.90. The firm sees risk to the company's margins in 2026 amid a period of uncertainty.

American Shared Hospital Announces Q3 EPS of 0c Compared to (3c) Last Year

Reports Q3 revenue $7.2M vs $6.999M last year. Gary Delanois, Chief Executive Officer, commented: "I am pleased to report revenue increases in both our three and nine-month results which were primarily driven by increased revenue in our direct patient care services segment as our new physicians in Rhode Island ramp up and volumes increase. Our new radiation therapy center in Puebla Mexico is off to a fantastic start where revenue has grown significantly. I am also gratified to see the period over period increase in Gamma Knife revenue in the third quarter, and we remain vigilant in driving the overall revenue growth of the Company. As we look into the remainder of this year and 2026, we expect further growth in revenue from the new Esprit being installed in our new Gamma Knife center in Guadalajara, Mexico that is expected to startup in the second quarter of 2026. We are also very pleased to announce the recent signing of an Existing Health System to a 10 Year Extension for an Esprit - the latest model Gamma Knife System."

American Shared Hospital reports Q2 EPS (4c) vs. 55c last year

Reports Q2 revenue $7.07M vs. $7.06M last year. Gary Delanois, Chief Executive Officer commented, "I am pleased to see patient volumes increased compared to last quarter and we remain laser focused on expanding our business model and operational enhancements to further position us for robust long-term growth. As we look into the second half of this year, we expect further long-term growth from the new Esprit being installed in Guadalajara, Mexico that is expected to startup in late 2025. Additionally, our recent Certificate of Need approvals for the first radiation therapy treatment center in Bristol, Rhode Island and a proton beam radiation therapy treatment center in Johnston, Rhode Island, also put us on track to further expand our Rhode Island footprint and growth potential. As we stay focused on targeted strategic initiatives to further improve efficiency and to take advantage of economies of scale to maximize profitability, our new business development pipeline, and strong balance sheet strengthens our position for our next phase of growth."